MX385144B - Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata. - Google Patents

Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.

Info

Publication number
MX385144B
MX385144B MX2017014184A MX2017014184A MX385144B MX 385144 B MX385144 B MX 385144B MX 2017014184 A MX2017014184 A MX 2017014184A MX 2017014184 A MX2017014184 A MX 2017014184A MX 385144 B MX385144 B MX 385144B
Authority
MX
Mexico
Prior art keywords
prostate cancer
antibody
treatment
integrin alpha
relates
Prior art date
Application number
MX2017014184A
Other languages
English (en)
Inventor
Axel Hoffmann
Benoit Destenaves
Frederic Christian Pipp
Heinrich Lannert
Juergen Reindl
Karin Groll
Klaus Brischwein
Michael Zuehlsdorf
Otmar Pfaff
Sabine Raab
Ulrike Dau
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX385144B publication Critical patent/MX385144B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al tratamiento del cáncer de próstata por medio de anticuerpos. Ante todo, la invención se refiere a la administración de un anticuerpo anti-integrina alfa v (receptor) a pacientes que sufren de cáncer de próstata, especialmente cáncer de próstata resistente a la castración (CRPC), acompañado opcionalmente por metástasis en los ganglios linfáticos y huesos (mCRPC). En particular, la invención se refiere a la terapia de los pacientes por medio del anticuerpo anti-angiogénico DI17E6 y mutantes estructurales del mismo.
MX2017014184A 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata. MX385144B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11001135 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX385144B true MX385144B (es) 2025-03-14

Family

ID=45569571

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009062A MX352025B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
MX2017014184A MX385144B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009062A MX352025B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.

Country Status (23)

Country Link
US (3) US9555110B2 (es)
EP (2) EP3415162A1 (es)
JP (2) JP6320042B2 (es)
KR (2) KR101972533B1 (es)
CN (1) CN103347540B (es)
AU (2) AU2012216145B2 (es)
CA (1) CA2827052C (es)
DK (1) DK2672994T3 (es)
EA (1) EA032117B1 (es)
ES (1) ES2683347T3 (es)
HR (1) HRP20181212T1 (es)
HU (1) HUE037212T2 (es)
IL (1) IL227687B (es)
LT (1) LT2672994T (es)
MX (2) MX352025B (es)
PL (1) PL2672994T3 (es)
PT (1) PT2672994T (es)
RS (1) RS57524B1 (es)
SG (1) SG192667A1 (es)
SI (1) SI2672994T1 (es)
TR (1) TR201810294T4 (es)
WO (1) WO2012107211A1 (es)
ZA (1) ZA201306807B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
BR112017005336A2 (pt) 2014-09-17 2017-12-12 Merck Patent Gmbh método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos
CN106714835A (zh) 2014-09-17 2017-05-24 默克专利股份公司 治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法
AU2016360661B2 (en) * 2015-11-23 2023-12-14 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP4637731A1 (en) 2022-12-21 2025-10-29 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
AU2003298783B2 (en) 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CN1953768B (zh) 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2008008435A2 (en) 2006-07-14 2008-01-17 Rutgers, The State University Methods, systems, and compositions for extracellular matrix production
ES2395799T3 (es) * 2007-07-17 2013-02-15 Merck Patent Gmbh Anticuerpos híbridos anti- integrina alfa V modificados genéticamente
US20110177155A1 (en) 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
EP2706358A3 (en) * 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
AU2010285265B2 (en) 2009-08-19 2015-05-21 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
JP2013510804A (ja) 2009-11-13 2013-03-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 化学療法剤を装荷したナノ粒子に結合した抗インテグリン抗体
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Also Published As

Publication number Publication date
IL227687A0 (en) 2013-09-30
CN103347540B (zh) 2016-05-25
MX2013009062A (es) 2013-10-01
WO2012107211A1 (en) 2012-08-16
AU2017200998A1 (en) 2017-03-09
US20170218070A1 (en) 2017-08-03
ZA201306807B (en) 2014-05-28
DK2672994T3 (en) 2018-07-16
EA201391147A1 (ru) 2014-01-30
CN103347540A (zh) 2013-10-09
US9555110B2 (en) 2017-01-31
IL227687B (en) 2019-02-28
HRP20181212T1 (hr) 2018-10-05
EA032117B1 (ru) 2019-04-30
JP2017066156A (ja) 2017-04-06
KR20140012087A (ko) 2014-01-29
CA2827052C (en) 2022-08-16
HUE037212T2 (hu) 2018-08-28
EP2672994B1 (en) 2018-05-09
AU2012216145B2 (en) 2016-11-17
PT2672994T (pt) 2018-10-22
AU2012216145A1 (en) 2013-09-26
SG192667A1 (en) 2013-09-30
TR201810294T4 (tr) 2018-08-27
KR20190044696A (ko) 2019-04-30
MX352025B (es) 2017-11-07
EP2672994A1 (en) 2013-12-18
KR102103701B1 (ko) 2020-04-23
US20140086908A1 (en) 2014-03-27
JP2014510047A (ja) 2014-04-24
ES2683347T3 (es) 2018-09-26
SI2672994T1 (sl) 2018-09-28
LT2672994T (lt) 2018-07-25
KR101972533B1 (ko) 2019-08-26
PL2672994T3 (pl) 2018-11-30
CA2827052A1 (en) 2012-08-16
HK1190094A1 (zh) 2014-06-27
JP6488273B2 (ja) 2019-03-20
EP3415162A1 (en) 2018-12-19
RS57524B1 (sr) 2018-10-31
AU2017200998B2 (en) 2018-08-09
JP6320042B2 (ja) 2018-05-09
US20190263913A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
NZ710929A (en) Antibody drug conjugates
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
UA109658C2 (xx) Антитіло проти cgrp
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA201590359A1 (ru) Лечение ревматоидного артрита
MX385144B (es) Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.